Parenteral amphotericin B has been considered as first-line therapy in the treatment of\nsystemic fungal and parasitic infections, however its use has been associated with a number of\nlimitations including affordability, accessibility, and an array of systemic toxicities. Until very recently,\nit has been very challenging to develop a bioavailable formulation of amphotericin B due to its\nphysical chemical properties, limited water and lipid solubility, and poor absorption. This perspective\nreviews several novel oral Amphotericin B formulations under development that are attempting to\novercome these limitations.
Loading....